Lifecycle Management of Process Analytical Technology Procedures

Similar documents
Guidance for Industry

Application of PAT for Tablet Analysis. Case examples from Novartis Lorenz Liesum, Lead PAT Hamburg, 19 th of April 2013

Validation of Pharmaceutical Manufacturing Process Focus: APIs.

Validation of Analytical Methods used for the Characterization, Physicochemical and Functional Analysis and of Biopharmaceuticals.

Validation/Verification of Test Methods An FDA Perspective. Laure H. Kairawicz, Ph.D. Senior Scientist Expert Witness

Guidance for Industry Process Validation: General Principles and Practices; A Contract Manufacturing Organization's Approach

The long anticipated draft of the FDA s

22 January Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, rm Rockville, MD 20852

MASTER PLANNING FOR VALIDATION

ISPE Annual Meeting 29 October 1 November 2017 San Diego, CA. FDA Perspective on the Use of Process Capability

Common Issues in Qualification and Validation of Analytical Procedures

Guidance for Industry Process Validation: General Principles and Practices. F. Hoffman-La Roche, Ltd.

Challenges of Implementation of FDA Guideline on Process Validation

Medicines Control Authority Of Zimbabwe

Practical Applications of Statistical Methods Under 2011 FDA Process Validation Guidance

Lifecycle of NIR Analytical Methods: Regulatory Perspective

QUALITY ASSESSMENT METHODS FOR NEW PRODUCT LAUNCHES: PROCESS VALIDATION LIFECYCLE

A Framework and Case Study for Implementing the New Process Validation Guidance

EMA NIRS Guideline, Reference

ABB Industries PAT Validation

Continuous Manufacturing: An Industry View

BIOEQUIVALENCE TRIAL INFORMATION

PROCESS VALIDATION Jaap Koster. Pharmaceutical Consultancy Services, All rights reserved.

Quality by Design Considerations for Analytical Procedures and Process Control

BIOEQUIVALENCE TRIAL INFORMATION FORM (Medicines and Allied Substances Act [No. 3] of 2013 Part V Section 39)

Process Validation Lifecycle Approach: A Return to Science

Systems-Based Inspections for Cleaning Validation

Stage 3 - Process Validation: Measuring what matters

Audit Validation Programs Like a Champ (When your time is limited!!) Cathelene Compton 12 October 2017

Managing Quality in Pharmaceutical Industry Using Six Sigma. Edited by Mahmoud Farouk Moussa TQM, CSSBB, MBA

SESSION 14. Documentation Requirements and Management for Validation. 30 March Frits Vogt

A COMPARATIVE FRAMEWORK BETWEEN NEW PRODUCT & LEGACY PRODUCT PROCESS VALIDATION

VALIDATION OF ANALYTICAL PROCEDURES: METHODOLOGY *)

Association. Case Study 3. achieving real time release testing by a

Demonstrating a High Degree of Assurance in Stage 2 of the Process Validation Lifecycle

EFFECTIVE MANAGEMENT OF THE PROCESS VALIDATION LIFECYCLE VALIDATION MASTER PLAN DEVELOPMENT

Understanding the Characteristics and Establishing Acceptance Criteria for Analytical Methods Validation

Analytical Method Transfer Program. Richard B. Nguyen. Associate Scientific Liaison, Chemical Medicines, USP

Validation & Transfer of Methods for

Perspectives on Method Validation: Importance of Adequate Method Validation

Regulatory Assessment

Continuous Pharmaceutical Manufacturing: CGMP, Process Validation, and Inspectional Considerations for Implementation

VICH Topic GL2 (Validation: Methodology) GUIDELINE ON VALIDATION OF ANALYTICAL PROCEDURES: METHODOLOGY

SCIENCE AND RISK BASED APPROACH TO THE PROCESS VALIDATION LINK FROM QUALITY BY DESIGN TO PROCESS VALIDATION.

á1225ñ VALIDATION OF COMPENDIAL PROCEDURES

Current Features of USFDA and EMA Process Validation Guidance

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL

3. Equipment Cleaning Validation for Active Pharmaceutical Ingredients (APIs) 8. Process Validation for Active Pharmaceutical Ingredients (API)

Process Validation Guidelines. Report highlights 23 rd February 2018

QbD Concepts Applied to Qualification and Transfer of Analytical Methods

International Journal of Pharmaceutical and Medicinal Research

GUIDE TO GOOD MANUFACTURING PRACTICE FOR MEDICINAL PRODUCTS

PROCESS VALIDATION ROCHAPON WACHAROTAYANKUN, PH.D.

TEMPLATE FOR AN EXAMPLE METHODS VALIDATION STANDARD OPERATING PROCEDURE (SOP)

Scientific and Regulatory Considerations for Continuous Manufacturing Implementation for Drug Product

Int. J. Pharm. Sci. Rev. Res., 34(1), September October 2015; Article No. 23, Pages: Process Validation of Tablet Dosage Form in Industries

Validation, Verification and Transfer of Analytical Methods (Understanding and implementing guidelines from FDA/EMA, USP and ICH)

NIRS, PAT, RTR testing EU experience and regulatory perspective

Lifecycle Approach to Process Validation

Implementation of Lifecycle Validation Practices at CMOs 1

Implementing Continuous Pharmaceutical Manufacturing: An FDA Perspective

FDA Quality Metrics Guidance

Lifecycle Product Quality Risk Management

Laboratory OOS Investigations The Missing Link

Validation of a concentration assay using Biacore C

Synopsis: FDA Process Validation Guidance

Regulatory Perspective on Analytical Method Validation During Product Development

Inspections, Compliance, Enforcement, and Criminal Investigations

Approval Application Form for Sakura Bloom Tablets

GOOD LABORATORY PRACTICE Agilent Cary 8454 UV-Visible Spectroscopy System

PMDA Perspective: Regulatory Updates on Process Validation Standard

ICH Q2(R1) A Primer. cgmp. GxP PIC/S SOP ISO QA/QC LOD/LOQ. Validation of Analytical Methods API EP FDA OECD GCP

INTERNATIONAL RESEARCH JOURNAL OF PHARMACY ISSN Review Article

Control strategy and validation. Emanuela Lacana PhD Office of Biotechnology Products CDER/FDA

PPQ-to-Approval Timelines Acceleration Approaches at BMS

Inspection. Implementation of ICH Q8, Q9, Q10

ICH Quality Implementation Working Group POINTS TO CONSIDER

COMPLIANCE BY DESIGN FOR PHARMACEUTICAL QUALITY CONTROL LABORATORIES INSIGHT FROM FDA WARNING LETTERS

Industry Perspective on Manufacturing in Early Development

Lifecycle Management Concepts to analytical Procedures: A compendial perspective. Horacio Pappa, Ph.D. Director - General Chapters U.S.

Real-time tablet API analysis: a comparison of a palm-size NIR spectrometer to HPLC method

Regulatory Aspects of Cleaning and Cleaning Validation. Larry Greenstein Quality Operations, Quality Unit, Bio-Technology General, Ltd.

GMP Challenges to Global Pharma Companies

Dal Quality by Design alla Process Validation nel processo di sviluppo di un medicinale

The Use of Stratified Sampling of Blend and Dosage Units to Demonstrate Adequacy of Mix for Powder Blends 1

Bioanalytical method validation: An updated review

PMDA Views on Applying Continuous Manufacturing to Pharmaceutical Products for Industry (provisional draft)

PROPOSAL FOR REVISION OF THE SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES: VALIDATION, APPENDIX 7:NON-STERILE PROCESS VALIDATION

Investigating OOS for Finished Product on the Stability Program. Presented by: Nicole Chang, QA Manager, Apotex Pty Ltd

Delivery of materials (usually finished product from a distribution center) to a first paying customer external to Site

QbD and the New Process Validation Guidance

GUIDANCE NOTES ON ANALYTICAL METHOD VALIDATION

Guidance for Industry

Traditional Validation - Downstream

Inspections, Compliance, Enforcement, and Criminal Investigations

Control Strategy. Implementation of ICH Q8, Q9, Q10

PAT for the On-line Characterization of Continuous Manufacturing Systems

At Your ServIce. Microbiology Services. The life science business of Merck operates as MilliporeSigma in the U.S. and Canada.

Guidelines for Process Validation of Pharmaceutical Dosage Forms

DEVELOPING AN IN VITRO RELEASE TESTING (IVRT) METHOD FOR THE VALIDATION OF SEMI-SOLID TOPICAL FORMULATIONS

Transcription:

Lifecycle Management of Process Analytical Technology Procedures IFPAC 2015 Marta Lichtig Senior Scientist in New Testing Technologies, ACS Member

Contents General Comparison : PV guide to NIR model development Basics Stage 1 Stage 2 Stage 3 Analytical methodology

General Many articles were published on process and product lifecycle management, analytical method lifecycle management nothing about PAT methods lifecycle management. WHY?

Because you can t really and trustingly use a NIR method if its lifecycle is not properly managed!

Comparison PV guide The basic principle of quality assurance is that a drug should be produced that is fit for its intended use. NIR The basic principle of quality assurance of a NIR model is that is fit for its intended use. 0.40 0.35 0.30 0.25 0.20 0.15 0.10 0.05 0.00 Example: Determining the end of API blending by NIR monitoring: Blending 19:26 19:33 19:40 19:48 19:55 20:02 20:09 0.5 0.4 0.3 0.2 0.1 0 API 1500 1700 1900 2100 2300 2500 0.1-

Comparison PV guide NIR Quality, safety, and efficacy are designed or built into the product. Quality cannot be adequately assured merely by in-process and finished-product inspection or testing. Specificity, accuracy, precision, linearity and robustness are designed or built into the model. Quality cannot be adequately assured merely by once-in-a lifetime method development and validation.

Comparison PV guide NIR Each step of a manufacturing process is controlled to assure that the finished product meets all quality attributes including specifications Each step of a measurement is controlled to assure that the results meet all requirements (accuracy and precision, detection of unusual samples). Each NIR model needs to have, as first step, the identification of the sample population to be the same as that used for the library building

Stage 1 Process Design Model Design The goal of this stage is to design a process suitable for routine commercial manufacturing that can consistently deliver a product that meets its quality attributes The goal of this stage is to design a model suitable for consistent routine testing of the product/controlling the process at a high confidence level. To define the purpose of the model, it s scope an limitations

Predicted LOD [%] Stage 1 Process Design Model Design Building and Capturing Process Knowledge and Understanding Building and Capturing Process/Product/Method Knowledge and Understanding Extended release product granulation 3 2.5 2 1.5 1 0.5 0 LOD curve Consecutive reading []

ED Stage 1 Process Design Model Design Establishing a Strategy for Process Control Establishing a plan (protocol) for feasibility study Example R&D batch 0.5 0.4 0.3 0.2 Blending MgSt addition 0.1 0 11:0011:0511:1011:1511:2011:2511:3011:3511:4011:4511:50 Green- API Time

Stage 2 Process Qualification Model Qualification Process Qualification- the process design is evaluated to determine if it is capable of reproducible commercial manufacture Process Qualification- the model design is evaluated to determine if it is capable of providing specific, reproducible, accurate and precise results, at a high confidence level. (Model validation)

Stage 2 Process Qualification Model Qualification Design of a Facility and Qualification of Utilities and Equipment Establishing: the optimal position for measurement Performing IQ/OQ/PQ of the instrument (is the calibration possible in the place of measurement? The instrument needs to be removed for calibration?...)

Stage 2 Process Performance Qualification (PPQ) Model Performance Qualification (Model Validation) PPQ protocol (how many batches?) Tests to be performed (in-process, release, characterization) and acceptance criteria for each significant processing step Validation protocol (how many batches? Library? External?) Tests to be performed USP <1119> (all?) and acceptance criteria for each parameter

Stage 2 In line quantitative model (e.g LOD) USP<1225> Analytical Performance Characteristics Accuracy Category I Yes Precision Yes (?) Specificity Detection Limit Yes No The precision of an analytical procedure is determined by assaying a sufficient number of aliquots of a homogeneous sample to be able to calculate statistically valid estimates of standard deviation or relative standard deviation (coefficient of variation). Quantitation Limit Linearity Range No Yes Yes

Stage 2 PPQ Performance Model Validation Routine production conditions (target values) Challenging conditions Criteria and process performance indicators that allow for a science- and riskbased decision about the ability of the process to consistently produce quality products. The criteria should include: Data acquisition (routine process) Extreme values Criteria and performance indicators that allow for a science- and risk-based decision about the ability of the model to consistently produce quality results. The criteria should include:

Stage 2 PPQ Performance Model Validation A description of the statistical methods to be used in analyzing all collected data (e.g., statistical metrics defining both intra-batch and inter-batch variability). A description of the statistical methods to be used in analyzing all collected data (pretreatment(s), PCA, MLR, etc)

Stage 2 PPQ Performance Model Validation Provision for addressing deviations from expected conditions and handling of nonconforming data. Data should not be excluded from further consideration in terms of PPQ without a documented, sciencebased justification. Provision for addressing deviations from expected conditions and handling of nonconforming data (handling of outliers). Outliers should not be excluded from the model without a documented, sciencebased justification.

Stage 2 PPQ Report Model Validation Report Review and approval of the protocol/report by appropriate departments and the quality unit. Discuss and cross-reference all aspects of the protocol. Summarize data collected and analyze the data, as specified by the protocol. Review and approval of the protocol/report by appropriate departments and the quality unit. Discuss and cross-reference all aspects of the protocol. Summarize data collected and analyze the data, as specified by the protocol.

Data Stage 3 - Continued Process Verification Process The goal of the third validation stage is continual assurance that the process remains in a state of control (the validated state) during commercial manufacture Model The goal of the third validation stage is continual assurance that the model remains in a state of control (the validated state) during routine use Time Series Plot of Calculated LOD (%), Reference Method LOD(%) Etodolac Tablets USP 400mg & 500mg External Validation Set+ Ongoning Evaluation Samples 6 5 4 Variable Calculated LOD (%) Reference Method LOD(%) 3 2 1 USL=3 UTL=2.5 Average =1.5 LTL=1 0 4 8 12 16 20 Index 24 28 32 36

Stage 3 - Continued Process Verification Process Evaluating the performance of the process identifies problems and determines whether action must be taken to correct, anticipate, and prevent problems so that the process remains in control Model Evaluating the performance of the model identifies problems and determines whether action must be taken to correct, anticipate, and prevent problems so that the model remains in control

Stage 3 - Continued Process Verification Process Procedures should describe how trending and calculations are to be performed and should guard against overreaction to individual events as well as against failure to detect unintended process variability. Model Procedures should describe how trending and calculations are to be performed and should guard against overreaction to individual events as well as against failure to detect unintended process variability or model drift.

Stage 3 - Continued Process Verification Process A process is likely to encounter sources of variation that were not previously detected or to which the process was not previously exposed Model A model is likely to encounter sources of variation that were not previously detected or to which the model was not previously exposed

Stage 3 - Continued Process Verification Process Data gathered during this stage might suggest ways to improve and/or optimize the process by altering some aspects of the process or product, such as the operating conditions (ranges and setpoints), process controls, component, or in-process material characteristics. Model Data gathered during this stage might suggest ways to improve and/or optimize the model by altering some aspects of the model.

Stage 3 - Continued Process Verification Model Data gathered during this stage might suggest ways to improve and/or optimize the model by altering some aspects of the model.

Stage 3 - Continued Process Verification Process change A description of the planned change, a well-justified rationale for the change, an implementation plan, and quality unit approval before implementation must be documented Model update A description of the planned change a well-justified rationale for the change, an implementation plan (revalidation protocol), and quality unit approval before implementation must be documented

ANALYTICAL METHODOLOGY Process Analytical methods supporting commercial batch release must follow CGMPs in parts 210 and 211 Model Analytical methods supporting model building must follow CGMPs in parts 210 and 211 (be validated)